These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 30474747)

  • 1. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.
    Iacovelli R; Cossu Rocca M; Galli L; Sabbatini R; De Giorgi U; Santini D; Facchini G; Mosca A; Atzori F; Zucali P; Fornarini G; Massari F; Buti S; Ricotta R; Masini C; Toscani I; Biasco E; Guida A; Lolli C; De Lisi D; Rossetti S; Terrone C; Scartozzi M; Miggiano C; Pastorino A; Bersanelli M; Carlo-Stella G; Pinto C; Nobili E; Nolè F; Tortora G; Porta C
    Anticancer Drugs; 2018 Aug; 29(7):705-709. PubMed ID: 29846246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China.
    Shi G; Park SH; Ren H; Xue M; Lu X; Dong P; Gao X
    J Med Econ; 2018 Dec; 21(12):1150-1158. PubMed ID: 30134758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
    Proskorovsky I; Benedict A; Negrier S; Bargo D; Sandin R; Ramaswamy K; Desai J; Cappelleri JC; Larkin J
    BMC Cancer; 2018 Dec; 18(1):1271. PubMed ID: 30567533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
    Facchini G; Rossetti S; Berretta M; Cavaliere C; Scagliarini S; Vitale MG; Ciccarese C; Di Lorenzo G; Palesandro E; Conteduca V; Basso U; Naglieri E; Farnesi A; Aieta M; Borsellino N; La Torre L; Iovane G; Bonomi L; Gasparro D; Ricevuto E; De Tursi M; De Vivo R; Lo Re G; Grillone F; Marchetti P; De Vita F; Scavelli C; Sini C; Pisconti S; Crispo A; Gebbia V; Maestri A; Galli L; De Giorgi U; Iacovelli R; Buonerba C; Cartenì G; D'Aniello C
    J Transl Med; 2019 Aug; 17(1):296. PubMed ID: 31464635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era.
    Numakura K; Muto Y; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
    Cancer Med; 2021 Sep; 10(17):5839-5846. PubMed ID: 34313025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma.
    Qin SK; Jin J; Guo J; Wang JW; Zhou FJ; Huang YR; Ren XB; Ye DW; Pan S; Sajben P; Wang Q
    Future Oncol; 2018 Aug; 14(18):1835-1845. PubMed ID: 29717651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
    Géczi L; Bodoky G; Rokszin G; Fábián I; Torday L
    Pathol Oncol Res; 2020 Oct; 26(4):2201-2207. PubMed ID: 32291570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
    Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
    BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.
    Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
    Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
    J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
    Konishi S; Hatakeyama S; Numakura K; Narita S; Inoue T; Saito M; Tokui N; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Narita S; Kawaguchi T; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1080-e1089. PubMed ID: 31416753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.